Tinkering with Blood: Optimizing the Coagulation System for Therapeutic Purposes.
Eduardo Anitua1,2,3, Sabino Padilla1,2,3
1Eduardo Anitua Foundation for Biomedical Research, 01007 Vitoria, Spain.
Bioengineering (Basel, Switzerland)
|December 30, 2025
Summary
Platelet-rich plasma (PRP) therapy utilizes growth factors from blood for tissue repair. Standardization and guidelines are needed to overcome challenges in PRP composition and application for better clinical outcomes.
Area of Science:
- Regenerative Medicine
- Biomaterials
- Tissue Engineering
Background:
- Blood is a vital fluid tissue rich in proteins essential for biological functions.
- The coagulation system, including platelets and plasma proteins, plays key roles in clotting, defense, and tissue repair.
- Platelet-rich plasma (PRP) mimics natural coagulation and hemostasis, acting as a delivery system for growth factors in regenerative therapies.
Purpose of the Study:
- To explore the potential of platelet-rich plasma (PRP) as an innovative autologous therapy.
- To discuss the processing of blood to manufacture PRP and its therapeutic properties.
- To address the challenges and controversies surrounding PRP heterogeneity and application.
Main Methods:
- Blood processing involves anticoagulation, centrifugation for fractionation, and plasma activation.
- PRP preparation aims to concentrate platelets and their associated growth factors.
- The study reviews existing literature on PRP manufacturing and application.
Main Results:
- PRP exhibits anti-inflammatory, trophic, antifibrotic, and antialgic properties.
- Variability in PRP composition and application methods leads to controversies and inconsistent clinical outcomes.
- Patient-specific factors like age can negatively impact PRP therapy effectiveness.
Conclusions:
- Standardizing PRP manufacturing processes is crucial for consistent therapeutic effects.
- Developing clear guidelines for PRP application is necessary to improve clinical outcomes.
- Exploring allogeneic PRP may offer a solution to overcome limitations associated with autologous treatments.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.6K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.6K
01:29Venous Thrombosis III: Interprofessional Care
257
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
257
01:20Extrinsic and Intrinsic Pathways of Hemostasis
11.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.8K
01:16Clot Retraction and Fibrinolysis
8.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.3K
01:09Coagulation
9.5K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
9.5K
01:06Coagulation
1.2K
Colloidal solids are solid particles suspended in solution. They are usually negatively charged, attracting a compact primary layer of positively charged ions, which attract more counterions to form an electrical double layer. Electrostatic repulsion between the charged double layers prevents the particles from colliding, stabilizing the colloids. These solids are often undesirable because they can contain toxins that are difficult to remove. Coagulation is a technique that helps aggregate and...
1.2K